CytoSorbents Corporation filed a Form 8-K on November 20, 2026, disclosing the entry on November 19, 2026, into securities purchase agreements for a direct offering of common stock and pre-funded warrants expected to raise approximately $4.0 million in gross proceeds.
Key Highlights
- Gross proceeds: The offering is expected to generate approximately $4.0 million before deducting placement agent fees, financial advisor fees, and other offering expenses, according to the filing.
- Net proceeds: The company estimates net proceeds of approximately $3.5 million after deductions.
- Shares offered: 556,681 common shares to institutional and accredited investors at $4.94 per share, and 96,527 shares to directors and certain executive officers at $5.18 per share.
- Pre-funded warrants: Up to 151,822 shares of common stock may be purchased via pre-funded warrants at $4.939 per warrant, exercisable at $0.001 per share.
- Planned use of proceeds: Approximately $3.0 million of outstanding principal under the Avenue Loan Agreement, plus a $52,500 prepayment fee and a $270,000 final payment, with the remainder for general corporate and working capital purposes.
- Placement agent warrants: H.C. Wainwright & Co., LLC will receive warrants to purchase 18,078 shares at an exercise price of $6.175 per share, expiring November 19, 2031.
- Financial advisor fee: WBB Securities, LLC will receive a financial advisory fee of $30,000 in connection with the offering.
CytoSorbents' November 2026 Direct Offering: Structure, Pricing, and Proceeds
According to the filing, CytoSorbents Corporation (NASDAQ:CTSO) entered into two securities purchase agreements on November 19, 2026, with certain institutional and accredited investors. The offering covers 556,681 common shares at $4.94 per share and 96,527 shares to directors and certain executive officers at $5.18 per share, which the filing describes as "the consolidated closing bid price of our Common Stock on The Nasdaq Capital Market on November 18, 2026." Certain purchasers received pre-funded warrants in lieu of common stock, covering up to 151,822 shares at a purchase price of $4.939 per warrant.
The filing states the offering was expected to close on or about November 20, 2026, subject to customary closing conditions. The securities were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-281062), initially filed July 26, 2024, and declared effective September 30, 2024, supplemented by a prospectus supplement filed November 20, 2026, under Rule 424(b)(5). The pre-funded warrants are exercisable immediately and carry a beneficial ownership limitation of 4.99% or 9.99% at the holder's election.
H.C. Wainwright & Co., LLC is acting as exclusive placement agent. The filing discloses that Wainwright will receive a cash fee of 6.0% of aggregate gross proceeds, reduced to 3.0% for proceeds from certain existing stockholders identified in the engagement letter, along with non-accountable expenses of $50,000, up to $100,000 for legal counsel and other expenses, and clearing costs not to exceed $15,950, subject to an aggregate cap of $165,950 on such expenses and reimbursements. The placement agent warrants are exercisable into 18,078 shares at $6.175 per share and expire November 19, 2031. Those warrants were not registered under the Securities Act and were offered under the exemption provided by Section 4(a)(2) of the Securities Act.
What Was Disclosed
CytoSorbents disclosed a direct securities offering of common stock and pre-funded warrants expected to raise approximately $4.0 million gross, with estimated net proceeds of approximately $3.5 million, primarily intended for repayment of outstanding debt under its Avenue Loan Agreement plus associated fees.




Please wait processing your request...